Tag Archives: NVS

Amgen’s Novel Migraine Treatment Gets Key Approval

Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen’s preventive treatment of migraine in adults. It is the first FDA-approved preventive migraine treatment in a new class of drugs, which work by blocking the activity of calcitonin gene-related peptide, which is believed to play a critical role in....More>>>

Amgen’s Novel Migraine Treatment Gets Key Approval

Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen’s preventive treatment of migraine in adults. It is the first FDA-approved preventive migraine treatment in a new class of drugs, which work by blocking the activity of calcitonin gene-related peptide, which is believed to play a critical role in....More>>>

Regeneron Unknown: Eylea Future Competition Effects

Regeneron Pharmaceuticals (NASDAQ:REGN) is best known for Eylea, which is used to treat wet AMD (age-related macular degeneration) and some other eye diseases with great success. After hearing the Q1 2018 Regeneron conference call and seeing the stock price at the low end of its 52-week range, I added REGN to my buy list. But then something came up to make me think again – the question of....More>>>

Momenta Pharmaceuticals Contemplates Its Future

After a delay in launching Glatopa 40 mg resulted in competition, Momenta Pharmaceuticals (NASDAQ:MNTA) has decided to conduct a strategic review to determine where it should put its limited cash resources — presumably partnering or selling the remaining less-important assets — making for a rather abstract first-quarterearnings update.

Momenta Pharmaceuticals results: The raw....More>>>

Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise

In my whole life, I have known no wise people (over a broad subject matter area) who didn’t read all the time – none, zero. Youd be amazed at how much Warren reads – and at how much I read. My children laugh at me. They think Im a book with a couple of legs sticking out.

– Charlie Munger

Nektar Therapeutics (NASDAQ:NKTR) is one of the most robust growers....More>>>